NRAS and cancer: A link between the cell cycle effects of NEK9 silencing and CDK4 suppression was suggested by pharmacological studies in which the CDK4 inhibitors palbociclib and ribociclib also induced a G1‐phase cell cycle arrest and senescence in the NRAS‐ and KRAS‐mutant cancer cell lines.